Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin

Laura Poupon(Inserm), Jérôme Busserolles(Inserm), Laëtitia Prival(Inserm), Mathieu Méleine(Inserm), David Balayssac(Inserm), David André Barrière(Université de Tours), Sylvain Lamoine(Inserm), Nicolas Kerckhove(Centre Hospitalier Universitaire de Clermont-Ferrand), Michel Lazdunski(Centre National de la Recherche Scientifique), Stéphane Lolignier(Inserm), Alain Eschalier(Université Clermont Auvergne), Fabrice Giraudet(Centre National de la Recherche Scientifique), Nicolas Authier(Inserm), Vanessa Pereira(Inserm), Damien Richard(Inserm), Youssef Aissouni(Inserm)
Neuropharmacology
July 26, 2018
Cited by 70


Related Papers